TARGET AUDIENCE
This activity is intended for medical oncologists, urologists and other healthcare professionals involved in the treatment of prostate cancer (PC).

OVERVIEW OF ACTIVITY
Nearly one million men each year are newly diagnosed with PC, making it the fifth most common cancer in both sexes combined and the second most common among men worldwide. In 2014 in the United States alone it is estimated that the disease will culminate in 233,000 new cases and 29,480 deaths. As such, PC has a tremendous global impact and has become the center of extensive ongoing clinical research. For this reason, the clinical management of PC is frequently in a state of evolution, necessitating rapid and consistent clinician access to emerging data sets of relevance to the continuous delivery of quality cross-functional care.

By providing access to the latest research developments and expert perspectives, these proceedings from an international case-based CME symposium held at the 2014 ESMO Annual Meeting in Madrid, Spain aim to assist medical oncologists, urologists and other healthcare professionals as they attempt to formulate optimal disease management strategies in the face of a constantly evolving body of knowledge.

LEARNING OBJECTIVES

• Explore emerging data on the use of cytotoxic therapy in the setting of hormone-sensitive advanced PC.
• Recall existing and emerging research information demonstrating the effects of secondary hormonal interventions on quality and quantity of life for chemotherapy-naïve or pretreated castration-resistant PC, and use this information to guide treatment planning for these patients.
• Consider available Phase III clinical trial data documenting the efficacy of radium-223 dichloride in patients with PC and bone metastases, and formulate strategies to use this novel radiopharmaceutical.
• Effectively apply evidence-based research findings in the determination of best-practice sequencing of available immunotherapeutic, chemotherapeutic and secondary hormonal agents for patients with metastatic PC.
• Explore the emerging data and active research evaluating novel agents in the setting of PSA-only recurrent or advanced PC, and discuss the biologic basis for their clinical activity.
• Counsel appropriately selected patients with recurrent, asymptomatic and symptomatic metastatic PC about availability of and participation in ongoing clinical trials.

ACCREDITATION STATEMENT

CME credit is no longer available for this issue

CREDIT DESIGNATION STATEMENT

CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.

CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Johann S de Bono, MBChB, MSc, PhD
Professor of Experimental Cancer Medicine and
Honorary Consultant in Medical Oncology
Head of Clinical Studies Division of Drug Development
Unit and of the Prostate Cancer Targeted Therapy Group
The Institute of Cancer Research and
Royal Marsden NHS Foundation Trust
Sycamore House
Sutton, Surrey, United Kingdom

Advisory Committee and Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc, Sanofi; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Sanofi.

Karim Fizazi, MD, PhD
Head of the Department of Cancer Medicine
Institute Gustave-Roussy
Professor in Oncology
University of Paris
Villejuif, France

Advisory Committee: Astellas, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Janssen Pharmaceuticals Inc, Millennium: The Takeda Oncology Company, Sanofi; Speakers Bureau: Amgen Inc, Astellas, Janssen Pharmaceuticals Inc, Sanofi.

Chris Parker, MD
Consultant in Clinical Oncology
Royal Marsden Hospital
Honorary Reader in Prostate Oncology
Institute of Cancer Research
Sutton, United Kingdom

Advisory Committee: Astellas, Bayer HealthCare Pharmaceuticals, Janssen Pharmaceuticals Inc; Consulting Agreement: BN ImmunoTherapeutics Inc; Contracted Research: Bayer HealthCare Pharmaceuticals; Speakers Bureau: Sanofi.

David I Quinn, MBBS, PhD
Medical Director, Norris Cancer Hospital and Clinics
Head, GU Cancer Section
Division of Cancer Medicine and Blood Diseases
USC/Norris Comprehensive Cancer Center
Los Angeles, California

Advisory Committee: Astellas, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Corporation, Genentech BioOncology, Janssen Pharmaceuticals Inc, Medivation Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc, Sanofi; Consulting Agreements: Astellas, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Dendreon Corporation, Genentech BioOncology, Janssen Pharmaceuticals Inc, Medivation Inc, Novartis Pharmaceuticals Corporation, Pfizer Inc, Roche Laboratories Inc; Other Remunerated Activities: Medivation Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Teva Oncology and VisionGate Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals.

Hardware/Software Requirements:
A high-speed Internet connection  
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: January 2015
Expiration date: January 2016